西安2021年8月17日 /美通社/ -- 西安天美生物科技股份有限公司（納斯達克代碼：BON））（“天美生物”或“公司”），一家在天然、健康和個人護理行業提供關鍵活性成分及解決方案的領先供應商，今天宣布其截至2021年3月31日的6個月的半年度財務業績。
2021年上半年財務亮點
管理層討論
“我們創新高的收入和收益的加速增長是我們作為上市公司首次公布業績的很好的答卷，并為天美作為上市公司起了一個良好的開端，”天美生物的董事長兼CEO胡永衛表示，“我們的行業知名品牌與優質產品相結合，為我們的客戶帶來了很高的價值主張，并為我們在這個市場需求增長的時期提升市場份額提供了堅實的基礎。今年到目前為止，我們在新業務上取得的成果以及正在開發中的產品銷售的趨勢也令我感到鼓舞。我們將繼續優化我們的銷售策略，著重大型企業客戶，并降低我們的制造成本，以支持可持續的長期盈利能力。我要感謝我們辛勤工作的團隊，公司的成功離不開他們的不懈努力，以及我們忠實的客戶對我們的信任。我們在玉門工廠的擴張的時機非常好。目前，市場對我們產品需求旺盛，產能的提升提高，將為公司銷售增長提供保障，更好滿足當前市場客戶的需求。而公司新生產基地可以幫助我們實現這一目標。我們相信，我們的獨有的技術、商業模式和戰略將使我們能夠獲得更多的市場份額，并保持增長勢頭?！?/p>
2021上半年產品（按類別）與上年相比增長總結：
收入增加（減少） |
毛利潤增加（減少） |
|
香料原料 |
133.0% |
226.9% |
膳食補充劑（固體飲料） |
338.4% |
306.0% |
生物活性食品原料 |
(69.7%) |
(79.0%) |
香料原料
膳食補充劑（固體飲料）
生物活性食品原料
管理費用從截至2020年3月31日的六個月的811,799美元減少到2021年同期的679,635美元，減少了132,164美元，或大約16.3%，主要是由于截至2021年3月31日的六個月內專業咨詢服務費用減少了197,327美元。公司在截至2020年3月31日的六個月內產生了較高的咨詢服務費用和較高的審計費用。
政府補貼以補貼形式獲得并確認為其他營業收入，在截至2021年3月31日和2020年3月31日的六個月里，總額分別為446,910美元和332,418美元。
凈利潤從截至2020年3月31日的六個月的160萬美元增加到2021年同期的230萬美元。
經營活動產生的凈現金在截至2021年3月31日的六個月期間為200萬美元，2020年同期為50萬美元。
稀釋后每股收益（“EPS”）為0.40美元，2020年同期為0.30美元。
我們鼓勵投資者查閱公司完整的財務報表和相關的披露資料，以了解更多信息。這些材料可在https://www.sec.gov/edgar/browse/?CIK=1816815&owner=exclude.中查閱。
報告期后事件
投資者電話會議和網絡直播
討論公司2021年上半年財務業績的網絡直播將于2021年8月17日美國東部時間上午8:30開始。網絡直播和相關PPT的獲取可以訪問公司的投資者網站 https://ir.bnlus.com/events-presentations/。對于無法觀看網絡直播的人，在活動結束后公司將在網站上提供錄制版本。
預先登記：https://dpregister.com/sreg/10159604/ec6c783af0
預先登記的呼叫者將得到一個會議密碼和獨有PIN碼，可以立即進入電話會議并繞過接線員。與會者可以在任何時候進行預先登記，包括在電話會議開始后。
無法互聯網接入或無法預先登記的人可以通過以下電話撥入：
美國免費電話：1-866-777-2509
國際收費電話：1-412-317-5413
西安天美生物科技股份有限公司
西安天美生物專注于膳食營養補充劑的生物活性成分的生產，如為食品制造商提供天然益生元；個人護理成分的生產，如為香水香料制造商提供從植物來源的香料原料，天然復配膳食補充劑生產，如固體飲料。欲了解更多信息，請訪問公司網站：www.bnlus.com.
安全港聲明
本新聞稿包含了1995年《私人證券訴訟改革法案》中的前瞻性聲明。前瞻性聲明包括了有關公司計劃、目標、戰略、未來事件或業績的聲明，以及其他假設和不包含歷史事件的聲明。當公司使用諸如“可能”、“將”、“打算”、“應該”、“相信”、“期望”、“預期”、“計劃”、“估計”等或其他類似的表達方式，并不與歷史事件有關，就是在做前瞻性聲明。前瞻性聲明不是對公司未來業績的保證，涉及風險和不確定性，可能會導致實際結果與前瞻性聲明中討論的公司預期有實質性的差異。這些陳述受不確定性和風險因素的印象，包括但不限于：公司的目標和戰略、公司的未來業務發展、公司產品和服務的需求、技術的變化、經濟狀況、中國天然健康和個人護理行業的發展及公司希望發展的其他國際市場、聲譽和品牌、競爭和定價的影響、政府法規、中國及公司希望發展的其他國際市場的經濟和商業狀況的變動，以及與上述任何情況相關的假設和公司提交給SEC報告中所陳述的其他風險。因此，我們提醒投資者不要過分依賴本新聞稿中的前瞻性陳述。公司向SEC提交的文件中討論了其他因素，這些文件可在www.sec.gov 上查閱。公司不承擔公開修訂本聲明日期之后出現的事件或情況的前瞻性聲明的義務。
更多信息，請聯系：
In the United States: |
In China: |
Maggie Zhang | Impact IR |
Sophie Zhang | Impact IR |
Phone: (646) 893-8916 |
Email: sophie.zhang@irimpact.com |
Email: maggie.zhang@irimpact.com |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(UNAUDITED) |
||||||||
As of |
||||||||
March 31, 2021 |
September 30, 2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash |
$ |
1,040,607 |
$ |
53,106 |
||||
Accounts receivable, net |
8,869,747 |
5,771,008 |
||||||
Inventories, net |
1,446,516 |
1,016,442 |
||||||
Advance to suppliers, net |
1,894,359 |
3,491,145 |
||||||
Deferred initial public offering costs |
984,162 |
510,079 |
||||||
Prepaid expenses and other current assets |
106,786 |
7,434 |
||||||
TOTAL CURRENT ASSETS |
14,342,177 |
10,840,214 |
||||||
Property, plant and equipment, net |
14,590,470 |
14,171,963 |
||||||
Intangible assets, net |
144,126 |
140,993 |
||||||
Right-of-use lease assets, net |
229,532 |
|||||||
Deferred tax assets, net |
37,032 |
49,059 |
||||||
TOTAL ASSETS |
$ |
29,343,337 |
$ |
25,202,229 |
||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES |
||||||||
Short-term loans |
$ |
1,823,215 |
$ |
1,289,081 |
||||
Current portion of long-term loans |
2,318,528 |
1,227,346 |
||||||
Third party loans |
- |
690,327 |
||||||
Accounts payable |
577,311 |
1,288,629 |
||||||
Due to related parties |
1,019,128 |
2,322,990 |
||||||
Taxes payable |
5,688,786 |
4,402,625 |
||||||
Accrued expenses and other current liabilities |
1,275,936 |
442,582 |
||||||
Finance lease liabilities, current |
148,983 |
33,389 |
||||||
Operating lease liability, current |
57,051 |
|||||||
TOTAL CURRENT LIABILITIES |
$ |
12,908,938 |
$ |
11,696,969 |
||||
Long-term loans |
2,106,180 |
2,482,251 |
||||||
Finance lease liabilities, noncurrent |
110,499 |
- |
||||||
Operating lease liability, noncurrent |
176,701 |
- |
||||||
TOTAL LIABILITIES |
15,302,318 |
14,179,220 |
||||||
COMMITMENTS AND CONTINGENCIES EQUITY |
||||||||
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, |
$ |
580 |
$ |
580 |
||||
Additional paid in capital |
5,567,873 |
5,251,205 |
||||||
Statutory reserve |
579,922 |
579,922 |
||||||
Retained earnings |
7,384,071 |
5,072,672 |
||||||
Accumulated other comprehensive income (loss) |
15,421 |
(388,102) |
||||||
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY |
13,547,867 |
10,516,277 |
||||||
Non-controlling interest |
493,152 |
506,732 |
||||||
Total equity |
14,041,019 |
11,023,009 |
||||||
TOTAL LIABILITIES AND EQUITY |
$ |
29,343,337 |
$ |
25,202,229 |
||||
*Retrospectively restated for effect of 1-for-3 shares reverse split. |
||||||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME |
||||||||
(UNAUDITED) |
||||||||
For the six months ended March 31, |
||||||||
2021 |
2020 |
|||||||
REVENUE |
$ |
11,698,830 |
$ |
7,149,785 |
||||
COST OF REVENUE |
(8,325,148) |
(4,597,617) |
||||||
GROSS PROFIT |
3,373,682 |
2,552,168 |
||||||
OPERATING EXPENSES |
||||||||
Selling expenses |
(52,666) |
(59,765) |
||||||
General and administrative expenses |
(679,635) |
(811,799) |
||||||
Research and development expenses |
(106,998) |
(128,481) |
||||||
Total operating expenses |
(839,299) |
(1,000,045) |
||||||
INCOME FROM OPERATIONS |
2,534,383 |
1,552,123 |
||||||
OTHER INCOME (EXPENSES) |
||||||||
Interest income |
294 |
451 |
||||||
Interest expense |
(197,168) |
(172,913) |
||||||
Unrealized foreign transaction exchange gain (loss) |
(65,691) |
(4,300) |
||||||
Government subsidies |
446,910 |
332,418 |
||||||
Other income |
41,548 |
136,482 |
||||||
Total other income (expenses) |
225,893 |
292,138 |
||||||
INCOME BEFORE INCOME TAX PROVISION |
2,760,276 |
1,844,261 |
||||||
INCOME TAX PROVISION |
(465,077) |
(249,766) |
||||||
NET INCOME |
2,295,199 |
1,594,495 |
||||||
Less: net income (loss) attributable to non-controlling interest |
(16,200) |
61,317 |
||||||
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED |
2,311,399 |
1,533,178 |
||||||
OTHER COMPREHENSIVE INCOME (LOSS) |
||||||||
Total foreign currency translation adjustment |
406,143 |
32,468 |
||||||
TOTAL COMPREHENSIVE INCOME |
2,701,342 |
1,626,963 |
||||||
Less: comprehensive income (loss) attributable to non-controlling |
(13,580) |
59,939 |
||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON |
$ |
2,714,922 |
$ |
1,567,024 |
||||
EARNINGS PER SHARE |
||||||||
Basic and diluted |
$ |
0.40 |
$ |
0.30 |
||||
WEIGHTED AVERAGE NUMBER OF SHARES |
||||||||
Basic and diluted* |
5,800,000 |
5,166,667 |
||||||
* Retrospectively restated for effect of reverse split.
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(UNAUDITED) |
||||||||
For the six months ended March 31, |
||||||||
2021 |
2020 |
|||||||
Cash flows from operating activities |
||||||||
Net income |
$ |
2,295,199 |
$ |
1,594,495 |
||||
Adjustments to reconcile net income to cash provided by operating |
||||||||
Allowance for doubtful accounts |
6,323 |
23,316 |
||||||
Depreciation and amortization |
117,888 |
134,457 |
||||||
Deferred income tax |
13,879 |
(19,459) |
||||||
Amortization of operating lease right-of-use assets |
26,195 |
- |
||||||
Unrealized foreign currency exchange loss |
65,691 |
4,300 |
||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(2,898,493) |
(410,656) |
||||||
Inventories |
(391,958) |
482,914 |
||||||
Advance to suppliers |
1,738,442 |
(1,787,999) |
||||||
Prepaid expenses and other current assets |
(99,108) |
17,251 |
||||||
Accounts payable |
(760,103) |
(809,818) |
||||||
Operating lease liabilities |
(21,975) |
- |
||||||
Taxes payable |
1,120,847 |
905,514 |
||||||
Accrued expenses and other current liabilities |
786,942 |
412,845 |
||||||
Net cash provided by operating activities |
1,999,769 |
547,160 |
||||||
Cash flows from investing activities |
||||||||
Purchase of property and equipment |
(715) |
(26,957) |
||||||
Capital expenditures on construction-in-progress |
- |
(403,911) |
||||||
Net cash used in investing activities |
(715) |
(430,868) |
||||||
Cash flows from financing activities |
||||||||
Proceeds from short-term loans |
943,517 |
601,833 |
||||||
Proceeds from long-term loans |
685,067 |
41,001 |
||||||
Repayment of short-term loans |
(457,729) |
(1,211,475) |
||||||
Repayment of long-term loans |
(109,382) |
- |
||||||
Proceeds from (repayment of) borrowings from related parties |
(1,391,813) |
393,367 |
||||||
Proceeds from (repayment of) third party loans |
(716,574) |
76,797 |
||||||
Principal payment from (repayment of) finance lease |
254,970 |
(195,863) |
||||||
Payment for deferred initial public offering costs |
(155,557) |
(42,705) |
||||||
Net cash used in financing activities |
(947,501) |
(337,045) |
||||||
Effect of changes of foreign exchange rates on cash |
(64,052) |
15,605 |
||||||
Net increase (decrease) in cash |
987,501 |
(205,148) |
||||||
Cash, beginning of year |
53,106 |
293,771 |
||||||
Cash, end of year |
$ |
1,040,607 |
$ |
88,623 |
||||
Supplemental disclosure of cash flow information |
||||||||
Cash paid for interest expense |
$ |
215,268 |
$ |
172,913 |
||||
Cash paid for income tax |
$ |
1,424 |
$ |
- |
||||
Supplemental disclosure of non-cash investing and financing activities |
||||||||
Amortization of share-based compensation for initial public offering |
$ |
316,668 |
$ |
- |
||||
Right-of-use assets obtained in exchange for operating lease |
255,811 |
- |
||||||
